HC Wainwright Reiterates Buy Rating on Beam Therapeutics, Sets $80 Target
HC Wainwright reiterated its Buy rating on Beam Therapeutics and set an $80 price target. The target implies 238.3% upside from the Oct. 14 close of $23.65.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.